Reduction of blood pressure fluctuations by telmisartan molecule especially in combination with calcium channel antagonist

2021 ◽  
Vol 14 (4) ◽  
pp. 410-416
Author(s):  
Maria Łukasiewicz ◽  
Artur Mamcarz
Keyword(s):  
Enzyme Inhibitors ◽  
Pressure Fluctuations ◽  
Angiotensin Converting Enzyme Inhibitors ◽  
Hypotensive Effect ◽  
Good Alternative ◽  
Converting Enzyme Inhibitors ◽  
Once Daily ◽  
Smoothness Index ◽  
High Smoothness ◽  
Single Pill

1.28 billion people suffer from hypertension, and its complications cause 10 million deaths each year. Effective antihypertensive therapy is therefore one of the priority tasks of health care. Achieving good BP control depends on many factors, but one of the primary ones is the use of maximally effective therapy in the simplest possible regimen. Amlodipine in combination with telmisartan in the single-pill combination, through its high smoothness index, makes it possible to achieve a satisfactory hypotensive effect lasting 24 h when taken once daily. This combination is also a good alternative for cardiovascularly burdened patients who cannot use angiotensin-converting enzyme inhibitors and for elderly patients, especially after stroke

Evaluation of Nephrotoxicity Associated with Once-Daily Administration of Aminoglycoside

1997 ◽  
Vol 13 (6) ◽  
pp. 258-262 ◽  
Author(s):  
Mojgan Nodoushani ◽  
David P Nicolau ◽  
Catherine M Hitt ◽  
Richard Quintiliani ◽  
Charles H Nightingale
Keyword(s):  
Risk Factors ◽  
Enzyme Inhibitors ◽  
Case Series ◽  
Retrospective Chart Review ◽  
Angiotensin Converting Enzyme Inhibitors ◽  
Nonsteroidal Antiinflammatory Drugs ◽  
Antiinflammatory Drugs ◽  
Intravenous Contrast ◽  
Converting Enzyme Inhibitors ◽  
Once Daily

Objective: To determine the potential risk factors associated with nephrotoxicity in patients receiving once-daily aminoglycoside (ODA) therapy. Design: Case series. Setting: Large community teaching hospital. Patients: Twenty-five patients considered nephrotoxic during ODA therapy. Main Outcome Measures: This study is a retrospective chart review of patients in whom nephrotoxicity developed during ODA therapy. Nephrotoxicity was defined as a rise in serum creatinine (SCr) concentration of 0.5 mg/dL or more above the preaminoglycoside baseline value. Patients were identified from our institutional ODA database. Based on the previously identified risk factors for aminoglycoside-associated nephrotoxicity with conventional aminoglycoside therapy published by Bertino et al., a data collection tool was developed. Collected data included demographic information, concurrently administered drugs, diagnostic agents used, and potential comorbidity risk factors. Results: Similar to what has been found in patients receiving conventional aminoglycoside regimens, numerous risk factors, such as the concomitant use of cephalosporins, loop diuretics, intravenous contrast dye, angiotensin-converting enzyme inhibitors, and nonsteroidal antiinflammatory drugs, may have been responsible for the rise in SCr observed in our study population. In addition, common comorbidity risk factors in this population were pleural effusion, pneumonia, decrease in systolic blood pressure to less than 80 mm Hg, and preexisting renal disease. Conclusions: Nephrotoxicity is the result of multifactorial processes and is not solely due to the ODA administration technique.

scholarly journals Calcium-Channel Blockers in Patients with Radial Artery Grafts.

2021 ◽  
Author(s):  
Marco Moscarelli ◽  
Mario Gaudino
Keyword(s):  
Calcium Channel ◽  
Radial Artery ◽  
Enzyme Inhibitors ◽  
Coronary Bypass ◽  
Angiotensin Converting Enzyme Inhibitors ◽  
Hypotensive Effect ◽  
Channel Blockers ◽  
Cardiac Events ◽  
Converting Enzyme Inhibitors ◽  
Post Hoc

The use of radial artery (RA) grafts for coronary bypass surgery has recently gained newer attention since it has been associated with significant reduction in the risk of midterm cardiac events. Surprisingly the use on the RA graft as second ‘best’ conduit has been limited among the surgical community. There may be several explanations for the little popularity of the RA graft; one of the reasons that could prevent surgeons to include the RA in the daily surgical armamentarium it is that patients with RA grafts may require postoperative calcium-channel blocker (CB) therapy. Due to the thick muscular wall, it seems possible that the RA would needs CB in order to prevent spasm and ameliorate patency. CBs are, however, associated with important side effects; also they have hypotensive effect that can hamper the use of other therapy such as beta-blocker or angiotensin-converting enzyme inhibitors. The evidence supporting the use of CB after RA graft (either in the early phase or as chronic calcium-blocker (CCB)) is weak. A the post-hoc analysis from the ‘RADIAL’ (Radial Artery Database International ALliance), showed that in patients with RA, the use of CB for at least 12 months was associated with better clinical and angiographic outcomes at mid-term follow-up, but confounders and bias may be responsible for the reported findings (as healthier patients are more likely to tolerate CB) . This review aims to summarize current evidences available on the topic and to serve as benchmark for evidence-based decision-making for CB prescription after RA grafting.

scholarly journals Enalapril in therapy of arterial hypertension in patients with juvenile obesity

1994 ◽  
Vol 40 (6) ◽  
pp. 25-26 ◽  
Author(s):  
Ye. V. Malyghina ◽  
G. A. Gherasimov ◽  
T. M. Atamanova
Keyword(s):  
Arterial Hypertension ◽  
Enzyme Inhibitors ◽  
Plasma Renin ◽  
Blood Lipid ◽  
Angiotensin Converting Enzyme Inhibitors ◽  
Hypotensive Effect ◽  
Negative Effects ◽  
Converting Enzyme Inhibitors ◽  
Drug Of Choice ◽  
Juvenile Obesity

Clinical efficacy of enalapril, a drug belonging to a group of angiotensin-converting enzyme inhibitors, was studied in patients with pubertal juvenile dyspituitarism (juvenile obesity) coursing with arterial hypertension. A reactive increase of plasma renin activity and reduced concentration of plasma aldosterone were revealed. The drug was characterized by a pronounced hypotensive effect. No negative effects on the blood lipid spectrum or carbohydrate metabolism were observed. The study showed that enalapril may be a drug of choice in the treatment of the hypertensive syndrome in patients with juvenile obesity.

Regulation of vasomotor tone in the afferent and efferent arterioles

2015 ◽  
Author(s):  
Karlhans Endlich ◽  
Rodger Loutzenhiser
Keyword(s):  
Capillary Pressure ◽  
Enzyme Inhibitors ◽  
Pressure Fluctuations ◽  
Angiotensin Converting Enzyme Inhibitors ◽  
Renal Perfusion ◽  
Renal Vasculature ◽  
Converting Enzyme Inhibitors ◽  
Glomerular Capillary ◽  
Glomerular Capillary Pressure ◽  
Renal Vessels

Pre-glomerular vessels are regulated by membrane potential alterations affecting the activity of L-type voltage-activated Ca2+ channels; whereas voltage-independent mechanisms regulate the efferent arteriole, notably influenced by angiotensin II and therefore by angiotensin converting enzyme inhibitors, and by non-steroidal anti-inflammatory drugs.These properties underlie the physiologic control of glomerular capillary pressure, for example, by prostaglandin E2, during conditions of reduced renal perfusion and the stabilization of glomerular capillary pressure when the kidney is exposed to pressure fluctuations. A wealth of hormones affects the tone of renal vessels. The chapter focuses on basic regulatory and signalling mechanisms, emphasizing the unique aspects of the renal vasculature and the underlying features that facilitate the independent regulation of pre-glomerular and post-glomerular tone.

Long-Acting Angiotensin-Converting Enzyme Inhibitors in Congestive Heart Failure: Does Multiple-Daily Dosing Provide Additional Benefit over Once-Daily Dosing?

2005 ◽  
Vol 21 (4) ◽  
pp. 203-206
Author(s):  
Myra T Belgeri
Keyword(s):  
Heart Failure ◽  
Congestive Heart Failure ◽  
Angiotensin Converting Enzyme ◽  
Ace Inhibitors ◽  
Enzyme Inhibitors ◽  
Angiotensin Converting Enzyme Inhibitors ◽  
Converting Enzyme ◽  
Converting Enzyme Inhibitors ◽  
Once Daily ◽  
Long Acting

Objective: To determine if there is clinical evidence supporting the use of twice-daily long-acting angiotensin-converting enzyme (ACE) inhibitors in congestive heart failure (CHF). Data Sources: Articles were identified through searches of MEDLINE and PubMed (1966–June 2005). Search terms included angiotensin-converting enzyme inhibitors, congestive heart failure, dosing, dosing schedules, captopril, enalapril, fosinopril, lisinopril, quinapril, ramipril, and trandolapril. Only articles published in English were included. Additionally, bibliographies of articles cited were used to identify additional articles. Study Selection and Data Extraction: All available articles identified by the data sources were reviewed and those deemed relevant to the review were included. Data Synthesis: Data have suggested that long-acting ACE inhibitors are more effective than short-acting ACE inhibitors for the treatment of CHF. A few ACE inhibitors approved for the treatment of CHF have twice-daily dosing schedules; these same ACE inhibitors have once-daily dosing schedules when used in the treatment of hypertension. Recent data propose greater adrenergic blockage, and, thus, decreased stimulation of the renin–angiotensin–aldosterone system, with the twice-daily dosing schedule of the long-acting ACE inhibitors. This controversy has led some providers to prescribe all long-acting ACE inhibitors twice daily in the setting of CHF, which, when unnecessary, can lead to decreased compliance, increased morbidity, and decreased quality of life. Conclusions: The available clinical studies comparing dosing schedules of long-acting ACE inhibitors have many limitations. Until a well-designed, randomized, double-blind trial of appropriate duration evaluating clinical outcomes is conducted, multiple-daily dosing schedules do not provide additional benefit over once-daily dosing schedules of long-acting ACE inhibitors in the treatment of CHF.

Sign in / Sign up

Export Citation Format

Share Document